Clinical Trials Logo

ALK Positive clinical trials

View clinical trials related to ALK Positive.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05132218 Recruiting - NSCLC Stage IV Clinical Trials

Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer

EFLRWR
Start date: October 19, 2021
Phase:
Study type: Observational

The experimental design is exploratory, single-arm, multi-center, real-world research. Ensatinib 225mg qd A prospective and exploratory real-world study of Ensatinib for ALK-positive advanced non-small cell lung cancer patients Test purposes Exploring the real world, Ensatinib is effective for the newly treated ALK+ advanced NSCLC 1. Efficacy and safety; 2. The relationship between molecular mechanism and curative effect; 3. Ensatinib resistance mechanism;

NCT ID: NCT02201992 Recruiting - Clinical trials for Stage IIIA Non-Small Cell Lung Cancer AJCC v7

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Start date: March 23, 2015
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.